Cure TV

Patrick Borgen, MD, shares his thoughts on the ethics and the efficacy of undergoing pre-emptive double mastectomy in women who have a BRCA mutation, which can greatly increase their risk for breast and ovarian cancers.

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Debu Tripathy, MD, editor-in-chief of CURE magazine, shares the latest research in metastatic breast cancer, including targeted drugs being tested in early-phase studies that appear promising, including the PARP inhibitor veliparib, the CDK4/6 inhibitor palbociclib and the anti-angiogenesis drug trametinib.